Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
508 0 |
SM ISO690:2012 ZOULIM, Fabien, LENZ, Oliver, MOSCALU, Iurie. JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection. In: Gastroenterology, 2020, nr. 2(159), pp. 521-533. ISSN 0016-5085. DOI: https://doi.org/10.1053/j.gastro.2020.04.036 |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Gastroenterology | ||||||
Numărul 2(159) / 2020 / ISSN 0016-5085 /ISSNe 1528-0012 | ||||||
|
||||||
DOI:https://doi.org/10.1053/j.gastro.2020.04.036 | ||||||
Pag. 521-533 | ||||||
|
||||||
Rezumat | ||||||
Background & Aims: JNJ-56136379 (JNJ-6379), a capsid assembly modulator that blocks hepatitis B virus (HBV) replication, was well tolerated and demonstrated dose-proportional pharmacokinetics in healthy participants in part 1 of its first clinical trial. In part 2, we have evaluated the safety, pharmacokinetics, and antiviral activity of multiple doses of JNJ-6379 in patients with chronic HBV infection. Methods: We performed a double-blind study of 57 treatment-naïve patients with HB e antigen-positive or -negative (74%) chronic HBV infection without cirrhosis. Patients were randomly assigned to groups given JNJ-6379 at 25 mg (100 mg loading dose), 75 mg, 150 mg, or 250 mg or placebo daily for 4 weeks with an 8-week follow-up period. Results: Twenty-three (56%) of 41 patients given JNJ-6379 had at least 1 adverse event (AE) during treatment, compared with 10 (63%) of 16 patients given placebo. No serious AEs were reported during the treatment period. Three patients (7%) given JNJ-6379 vs none given placebo had grade 3 AEs; of these, 1 patient (150 mg) also had an isolated grade 4 increase in the level of alanine aminotransferase that led to treatment discontinuation. JNJ-6379 exposure increased with dose, with time-linear pharmacokinetics. HBV-DNA and HBV-RNA decreased from baseline in patients receiving all doses of JNJ-6379, independently of viral genotype and HB e antigen status. On day 29, 13 (32%) of 41 patients had levels of HBV DNA below the lower limit of quantification. No clinically significant changes in levels of HB surface antigen were observed. Conclusions: In a phase 1 study of treatment-naïve patients with chronic HBV infection, all doses tested of JNJ-6379 were well tolerated, showed dose-dependent pharmacokinetics, and had potent antiviral activity in patients with CHB. The findings support a phase 2a study to evaluate JNJ-6379 ± nucleos(t)ide analogs in patients with chronic HBV infection, which is under way. ClinicalTrials.gov identifier: NCT02662712 |
||||||
Cuvinte-cheie drug, HBeAg, HBsAg, liver |
||||||
|